Hepatic artery infusion with 5-fluorouracil and mitomycin-c in metastatic colorectal carcinoma phase ii study
โ Scribed by Theodors, Asgeir ;Bukowski, Ronald M. ;Lavery, Ian ;Hewlett, James S. ;Livingston, Robert B. ;Buonocore, Edward
- Publisher
- John Wiley and Sons
- Year
- 1982
- Tongue
- English
- Weight
- 532 KB
- Volume
- 10
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
โฆ Synopsis
Abstract
Thirtyโtwo patients with hepatic metastases colorectal carcinoma were treated with hepatic artery infusion (HAI) employing 5โfluorouracil (5โFU) and mitomycinโC (mitoโC). Catheters were placed percutaneously via the femoral artery. Two schedules were employed: (I) 5โFU 1,200 mg/m^2^ IA (D1โ4) and mitoโC 8 mg/m^2^ IA (D1 +D4); (2) 5โFU 1,200 mg/m^2^ IA (D1โ6) and mitoโC 8 mg/m^2^ IA (D1 +D4). Courses were repeated every 4 weeks. Thirty patients with measurable disease were evaluable, 22 received schedule I and 8 patients schedule II. Complete response occurred in two patients (6.7%) and partial response in 13 patients (43.3%). Five patients (16.7%) had minimal regression. The overall response rate was 66.7%. Median survival of all patients from start of treatment was 11.2 months. Median survival of responders and nonresponders was 12.4 months and 4.6 months, respectively (P <0.05). No differences in response rates, duration of response, or survival was seen between the two schedules. Drug toxicity was moderate to severe, but morbidity of HAI per se was minimal. Intermittent HAI of 5โFU and mitoโC is a wellโtolerated treatment modality associated with few serious complications. The response rate, duration of response, and the survival is comparable to continuous HAI infusion of 5โFU or floxuridine (FUDR). As given in this study, mitoโC did not appear to provide added benefit.
๐ SIMILAR VOLUMES
Twenty-seven patients with measurable liver metastases from colorectal carcinoma were entered on a protocol of intermittent hepaticartery infusion (HAI) of 5-fluorouracil(5-FU) followed by consolidation with hepatic irradiation. Five partial responses were observed in 23 evaluable patients. Median d
improvement in drug response and reduction of toxicity were observed after continuous intrahepatic arterial infusion of mytomycin-C (MMC) and 5-fluorouracil (5-FU) in 15 of 26 patients with primary or metastatic carcinoma of the liver. Serum bilirubin values of 10 mg/100 ml absence of ascites, extre
The combination of 5-fluorouracil and cisplatin has shown encouraging results in single institution pilot studies in colorectal carcinoma. This phase II SWOG study was undertaken to further evaluate this treatment. Cisplatin was administered at a dose of 60 mg/M2 IV day 1, repeated every 21 days. 5-